Variations in the BDNF measurement procedures and techniques (as pointed out in the study by Hirsch et al. [49]), protocol and settings of physical activity programs, and the ratio of included participants with RRMS or progressive MS in the included investigations might be other contributors to the heterogeneity in the meta-analysis results. The gene discussed is BDNF; the disease is myeloid sarcoma.